Conference abstract
A clinical trial to evaluate the safety and immunogenicity of a novel DNA vaccine used as immunotherapy during leishmaniasis
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Twenty leishmaniotic dogs from a leishmaniasis-endemic area (Naples, Italy) were enrolled in a clinical trial and were randomly assigned to receive three consecutive subcutaneous injections of vaccine at 10-days intervals (n=10\20), saline placebo (n=10\20). The vaccine was safe and well tolerated. Leishmania DNA load, IFAT, INF-λ and IL4 mRNA expression levels were tested before and after the immunotherapy, every 3 months for a period of 12 months. Analysis of the data indicated that the vaccine was safe and immunogenic in CVL dogs.
Keywords
Subjects
NanotechnologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nanomedicine & Nanotechnology
- SubjectNanotechnology
- BylineArticles whose byline prints “Laura Manna”
